Pyxis Oncology (PYXS) Accumulated Depreciation & Amortization (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Accumulated Depreciation & Amortization data on file, last reported at $7.0 million in Q4 2025.

• Quarterly Accumulated Depreciation & Amortization rose 33.9% year-over-year to $7.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.0 million (up 33.9% YoY) and the FY2025 annual result came in at $7.0 million, up 33.9% from the prior year.
• Accumulated Depreciation & Amortization improved to $7.0 million in Q4 2025 per PYXS's latest filing, from $5.2 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $7.0 million in Q4 2025 and bottomed at $1.1 million in Q4 2021.
• The 5-year median for Accumulated Depreciation & Amortization is $3.6 million (2023), against an average of $3.8 million.
• The widest annual swing landed in 2021, when Accumulated Depreciation & Amortization surged 137.95%; it then soared 33.9% in 2025.
• Tracing PYXS's Accumulated Depreciation & Amortization over 5 years: stood at $1.1 million in 2021, then surged by 63.53% to $1.8 million in 2022, then soared by 97.37% to $3.6 million in 2023, then surged by 45.28% to $5.2 million in 2024, then soared by 33.9% to $7.0 million in 2025.
• Per Business Quant, the three latest PYXS Accumulated Depreciation & Amortization figures stand at $7.0 million (Q4 2025), $5.2 million (Q4 2024), and $3.6 million (Q4 2023).

Peer Comparison